Biomedical Research Education & Training
Faculty Member

Clark, Peter E., M.D.
Professor of Urologic Surgery

Lab Url: N/A

Phone Number: 615 322-3807

Email Address:

Clark, Peter's picture
Academic history
B.A., Cornell
M.D., Harvard
, Cleveland Clinic Foundation
, University of Southern California

Office Address   Mailing Address

1302 Medical Center North, Nashville TN 37232-2765

A-1302 MCN 37232-2765

Clinical Research Keywords
Urologic Oncology including cancer of the kidney, bladder, prostate, testis, and penis

Patient Care Specialty
Urologic Oncology, including the surgical management of kidney, bladder, prostate, testis, and penile cancer.

Research Specialty
Urologic Oncology and Molecular Biology of Kidney Cancer

Borden, LS, Clark, PE, Lovato, J, Hall, MC, Stindt, D, Harmon, M, M Mohler, R, Torti, FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer, 107(5), 1093-100, 2006

Clark, PE, Hall, MC, Borden, LS, Miller, AA, Hu, JJ, Lee, WR, Stindt, D, D''Agostino, R, Lovato, J, Harmon, M, Torti, FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology, 67(6), 1257-61, 2006

Gwynn, ES, Clark, PE. Bladder cancer. Curr Opin Oncol, 18(3), 277-83, 2006

Lockett, KL, Hall, MC, Clark, PE, Chuang, SC, Robinson, B, Lin, HY, Su, LJ, Hu, JJ. DNA damage levels in prostate cancer cases and controls. Carcinogenesis, 27(6), 1187-93, 2006

Rackley, JD, Clark, PE, Hall, MC. Complementary and alternative medicine for advanced prostate cancer. Urol Clin North Am, 33(2), 237-46, viii, 2006

Rossi, PJ, Clark, PE, Papagikos, MA, McCullough, DL, Lee, WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology, 67(2), 349-53, 2006

Borden, LS, Clark, PE, Hall, MC. Bladder cancer. Curr Opin Oncol, 17(3), 275-80, 2005

Clark, PE, Farver, CF, Ulchaker, JC, Angermeier, K. A rare case of an extra-adrenal myelolipoma arising in the renal sinus: a case report and review of the literature. ScientificWorldJournal, 5, 109-17, 2005

Clark, PE, Hall, MC. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer. Urol Clin North Am, 32(2), 199-206, 2005

Clark, PE, Stein, JP, Groshen, SG, Cai, J, Miranda, G, Lieskovsky, G, Skinner, DG. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer, 104(1), 36-43, 2005

Clark, PE, Stein, JP, Groshen, SG, Cai, J, Miranda, G, Lieskovsky, G, Skinner, DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer, 103(3), 546-52, 2005

Gwynn, ES, Clark, PE. Inflammatory myofibroblastic tumor associated with renal cell carcinoma. Urology, 66(4), 880, 2005

Gwynn, ES, Clark, PE, Hall, MC. Recent advances in the treatment of bladder cancer. Expert Rev Anticancer Ther, 5(6), 1023-30, 2005

Papagikos, MA, Deguzman, AF, Rossi, PJ, McCullough, DL, Clark, PE, Lee, WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90). Brachytherapy, 4(4), 252-8, 2005

Borden, LS, Clark, PE, Hall, MC. Bladder cancer. Curr Opin Oncol, 16(3), 257-62, 2004

Clark, PE, Hall, MC, Miller, A, Ridenhour, KP, Stindt, D, Lovato, JF, Patton, SE, Brinkley, W, Das, S, Torti, FM. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology, 63(6), 1061-5, 2004

Clark, PE, Stein, JP, Groshen, SG, Miranda, G, Cai, J, Lieskovsky, G, Skinner, DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol, 172(4 Pt 1), 1342-7, 2004

Clark, PE, Streem, SB. Endourologic management of upper tract transitional cell carcinoma. ScientificWorldJournal, 4 Suppl 1, 62-75, 2004

Clark, PE, Veys, JA, Eskridge, MR, Woodruff, RD, Hall, MC. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urol Oncol, 23(5), 328-32, 2004

Kubinski, DJ, Clark, PE, Assimos, DG, Hall, MC. Utility of frozen section analysis of resection margins during partial nephrectomy. Urology, 64(1), 31-4, 2004

Lockett, KL, Hall, MC, Xu, J, Zheng, SL, Berwick, M, Chuang, SC, Clark, PE, Cramer, SD, Lohman, K, Hu, JJ. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res, 64(17), 6344-8, 2004

Matlaga, BR, Zagoria, RJ, Clark, PE, Hall, MC. Radiofrequency ablation of renal tumors. Curr Urol Rep, 5(1), 39-44, 2004

Quek, ML, Stein, JP, Clark, PE, Daneshmand, S, Miranda, G, Cai, J, Groshen, S, Cote, RJ, Lieskovsky, G, Quinn, DI, Skinner, DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol, 171(2 Pt 1), 640-5, 2004

Zagoria, RJ, Hawkins, AD, Clark, PE, Hall, MC, Matlaga, BR, Dyer, RB, Chen, MY. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR Am J Roentgenol, 183(1), 201-7, 2004

Borden, LS, Clark, PE, Hall, MC. Bladder cancer. Curr Opin Oncol, 15(3), 227-33, 2003

Clark, PE, Irvine, RA, Coetzee, GA. The androgen receptor CAG repeat and prostate cancer risk. Methods Mol Med, 81, 255-66, 2003

Clark, PE, Torti, FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res(415 Suppl), S148-57, 2003

Jia, L, Kim, J, Shen, H, Clark, PE, Tilley, WD, Coetzee, GA. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res, 1(5), 385-92, 2003

Quek, ML, Stein, JP, Clark, PE, Daneshmand, S, Miranda, G, Cai, J, Groshen, S, Lieskovsky, G, Quinn, DI, Raghavan, D, Skinner, DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer, 98(5), 955-61, 2003

Clark, PE. Urinary diversion after radical cystectomy. Curr Treat Options Oncol, 3(5), 389-402, 2002

Wilson, SS, Clark, PE, Stein, JP. Angiomyolipoma with vena caval extension. Urology, 60(4), 695-6, 2002

Clark, PE, Novick, AC. Exophytic noninvasive growth pattern of renal angiomyolipomas: implications for nephron sparing surgery. J Urol, 165(2), 513-4, 2001

Clark, PE, Peereboom, DM, Dreicer, R, Levin, HS, Clark, SB, Klein, EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology, 57(2), 281-5, 2001

Clark, PE, Schover, LR, Uzzo, RG, Hafez, KS, Rybicki, LA, Novick, AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology, 57(2), 252-6, 2001

Clark, PE, Klein, EA. Surgery for invasive bladder tumors: technique and outcome. Curr Opin Urol, 9(5), 413-8, 1999

Clark, PE, Streem, SB, Geisinger, MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol, 161(3), 772-5; discussion 775-6, 1999

Uzzo, RG, Clark, PE, Rayman, P, Bloom, T, Rybicki, L, Novick, AC, Bukowski, RM, Finke, JH. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst, 91(8), 718-21, 1999

Uzzo, RG, Rayman, P, Kolenko, V, Clark, PE, Bloom, T, Ward, AM, Molto, L, Tannenbaum, C, Worford, LJ, Bukowski, R, Tubbs, R, Hsi, ED, Bander, NH, Novick, AC, Finke, JH. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res, 5(5), 1219-29, 1999

Uzzo, RG, Rayman, P, Kolenko, V, Clark, PE, Cathcart, MK, Bloom, T, Novick, AC, Bukowski, RM, Hamilton, T, Finke, JH. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest, 104(6), 769-76, 1999 PMCID:408430

Capelouto, CC, Clark, PE, Ransil, BJ, Loughlin, KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary. J Urol, 153(3 Pt 2), 981-5, 1995

Postdoctoral Position Available

Postdoctoral Position Details

Updated Date